Changes in 18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

Br J Cancer. 2000 Aug;83(3):281-3. doi: 10.1054/bjoc.2000.1342.
No abstract available

Publication types

  • Editorial
  • Review
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Europe
  • Fluorodeoxyglucose F18* / metabolism
  • Glucose / metabolism
  • Humans
  • Neoplasms / diagnostic imaging
  • Neoplasms / drug therapy
  • Neoplasms / metabolism*
  • Pancreatic Neoplasms / metabolism
  • Practice Guidelines as Topic
  • Predictive Value of Tests
  • Radiopharmaceuticals* / metabolism
  • Sensitivity and Specificity
  • Tissue Distribution
  • Tomography, Emission-Computed* / methods

Substances

  • Antineoplastic Agents
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Glucose